Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)

This publication has 10 references indexed in Scilit:

• A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)
  Blood, 2015
• Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments
  Drugs & Aging, 2015
• SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia
  British Journal of Haematology, 2014
• Acute Myeloid Leukemia, Version 2.2013
  Journal of the National Comprehensive Cancer Network, 2013
• Salvage therapy using FLT3 inhibitors may improve long‐term outcome of relapsed or refractory AML in patients with FLT3‐ITD
  British Journal of Haematology, 2013
• Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia
  Blood, 2012
• Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study
  Blood, 2006
• Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells
  Blood, 2004
• Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
  Journal of Clinical Oncology, 2003
• A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [letter]
  Blood, 1996